ロード中...
Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia
Dasatinib is a potent dual Abl/Src inhibitor approved for treatment of Ph-positive leukemias. At a once-daily dose and a relatively short half-life of 3-5 hours, tyrosine kinase inhibition is not sustained. However, transient inhibition of K562 leukemia cells with a high-dose pulse of dasatinib or l...
保存先:
| 主要な著者: | , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2010
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3038787/ https://ncbi.nlm.nih.gov/pubmed/20111071 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2009.302 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|